COFFEE AND CHAT
'Coffee and Chat' Highlights: Professor Chloe Orkin and Nurse specialist Jonathan Roberts
Two experts in conversation: Professor Chloe Orkin and Nurse specialist Jonathan Roberts share their reflections of long acting injectables in the context of shared decision-making and discussing risks and benefits with patients.
‘COFFEE AND CHAT’ FULL CONVERSATIONS
Professor Chloe Orkin and Nurse Specialist Jonathan Roberts
Professor Chloe Orkin and Nurse specialist Jonathan Roberts share their reflections of long acting injectables in the context of shared decision-making and discussing risks and benefits with patients.
Nurse Consultant Laura Hilton
Nurse Consultant Laura Hilton shares her reflections of long acting injectables in the context of patient adherence and concordance.
Sound of Science Podcast
SOUND OF SCIENCE: EPISODE 1
Listen to Prof. Chloe Orkin and Dr. Perry Mohammed review the SOLAR data.
PM-GB-CBR-WCNT-230018 | January 2024
UK National Webinar Recordings
PM-GB-CBR-VID-220008 | November 2022
PM-GB-CBR-VID-220005 | November 2022
PM-GB-CBR-VID-220006 | November 2022
PM-GB-CBR-VID-220007 | November 2022
PM-GB-CBR-VID-220010 | November 2022
PM-GB-CBR-VID-220004 | November 2022
PM-GB-CBR-VID-220009 | November 2022
REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
PM-GB-CBR-WCNT-230017 | June 2024
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
